Artritis Reumatoide y embarazo. Actualización

Elías  Rojas; Sonia Cabrera Villalba

doi:10.18004/rpr/2020.06.01.36-47

Vol. 6 No. 1 (2020), REVIEWS

Vol. 6 No. 1 (2020)

Rheumatoid Arthritis and Pregnancy. Upgrade

REVIEWS

Published 2020-06-24

Elías Rojas⁺⁻
Sonia Cabrera Villalba⁺⁻

Elías Rojas

Universidad Nacional de Asunción, Facultad de Ciencias Médicos, Departamento de Reumatología. San Lorenzo, Paraguay

Sonia Cabrera Villalba

Universidad Nacional de Asunción, Facultad de Ciencias Médicos, Departamento de Reumatología. San Lorenzo, Paraguay

PDF (Spanish)

Keywords

Rheumatoid Arthritis
pregnancy

How to Cite

1.

Rojas E, Cabrera Villalba S. Rheumatoid Arthritis and Pregnancy. Upgrade. Rev. parag. reumatol. [Internet]. 2020 Jun. 24 [cited 2025 Oct. 6];6(1):36-47. Available from: https://www.revista.spr.org.py/index.php/spr/article/view/119

Abstract

Rheumatoid Arthritis (RA) is a frequent chronic inflammatory autoimmune condition, characterized by persistent inflammation of synovial joints. Managing RA during pregnancy is complex, considering the need for an appropriate balance between monitoring disease activity and mitigating symptoms with non-toxic but effective therapies.

During pregnancy, a decrease in disease activity can be observed in 48 to 86% of patients. Some RA patients may develop flares, as well as pregnancy complications such as preterm labor, low birth weight and miscarriage.

NSAIDs may increase the risk of subfertility in patients with RA. Hydroxychloroquine and sulfasalazine can be safely administered throughout pregnancy. Glucocorticoids at doses greater than 7.5mg/day prednisone or equivalent were associated with preterm delivery. During the first trimester of pregnancy, continuation of anti-TNF therapy is recommended. Both Leflunomide and Methotrexate should be discontinued when pregnancy is being planned.

PDF (Spanish)

References

(1) Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2005;72(6):1037-47.

(2) Hunt N, Talabi MB. Family Planning and Rheumatoid Arthritis. Current rheumatology reports. 2019;21(5):16.

(3) Conigliaro P, Triggianese P, De Martino E, Chimenti MS, Sunzini F, Viola A, et al. Challenges in the treatment of Rheumatoid Arthritis. Autoimmunity reviews. 2019.

(4) Giles I, Yee C-S, Gordon C. Stratifying management of rheumatic disease for pregnancy and breastfeeding. Nature Reviews Rheumatology. 2019;15(7):391-402.

(5). Wallenius M, Salvesen KA, Daltveit AK, Skomsvoll JF. Secular trends of pregnancies in women with inflammatory connective tissue disease. Acta Obstet Gynecol Scand. 2015;94(11):1195-202.

(6) Wallenius M, Skomsvoll JF, Irgens LM, Salvesen KA, Nordvag BY, Koldingsnes W, et al. Parity in patients with chronic inflammatory arthritides childless at time of diagnosis. Scand J Rheumatol. 2012;41(3):202-7.

(7) Walldorf J, Brunne S, Gittinger FS, Michl P. Family planning in inflammatory bowel disease: childlessness and disease-relatedconcerns among female patients. Eur J Gastroenterol Hepatol. 2018;30(3):310-5.

(8) Brouwer J, Hazes JM, Laven JS, Dolhain RJ. Fertility in women with rheumatoid arthritis: influence of disease activity and medication.Ann Rheum Dis. 2015;74(10):1836-41.

(9) Leroy C, Rigot JM, Leroy M, Decanter C, Mapihan KL, Parent AS, et al. Immunosuppressive drugs and fertility. Orphanet J Rare Dis. 2015;10:136.

(10) Clowse ME, Chakravarty E, Costenbader KH, Chambers C, Michaud. K. Effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2012;64(5):668-74.

(11) Key statistics from the National Survey of Family Growth, (2016).

(12) de Man YA, Dolhain RJ, Geijn FEvd, Willemsen SP, Hazes JM. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum. 2008;59(9):1241-8.

(13) Ostensen M, Fuhrer L, Mathieu R, Seitz M, Villiger PM. A prospective study of pregnant patients with rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments. Ann Rheum Dis. 2004;63(10):1212-7.

(14) De Man Y, Bakker-Jonges L, Dufour-Van Den Goorbergh C, Tillemans S, Hooijkaas H, Hazes J, et al. Women with rheumatoid arthritis negative for anti-cyclic citrullinated peptide and rheumatoid factor are more likely to improve during pregnancy, whereas in autoantibody-positive women autoantibody levels are not influenced by pregnancy. Annals of the rheumatic diseases. 2010;69(2):420-3.

(15) Barrett JH, Brennan P, Fiddler M, Silman AJ. Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum. 1999;42(6):1219-27.

(16) Brandt Svd, Zbinden A, Baeten D, Villiger PM, Ostensen M, Forger F. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients. Arthritis Res Ther. 2017;19(1):64.

(17) Kishore S, Mittal V, Majithia V, editors. Obstetric Outcomes in Women with Rheumatoid Arthritis: Results from Nationwide Inpatient Sample Database 2003-2011. Seminars in Arthritis and Rheumatism; 2019: Elsevier.

(18) Remaeus K, Johansson K, Askling J, Stephansson O. Juvenile onset arthritis and pregnancy outcome: a population-based cohort study. Ann Rheum Dis. 2017;76(11):1809-14.

(19) Zrour SH, Boumiza R, Sakly N, Mannai R, Korbaa W, Younes M, et al. The impact of pregnancy on rheumatoid arthritis outcome: the role of maternofetal HLA class II disparity. Joint Bone Spine. 2010;77(1):36-40.

(20) Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, et al. Placental transfer of anti–tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clinical Gastroenterology and Hepatology. 2013;11(3):286-92.

(21) Kahn DA, Baltimore. D. Pregnancy induces a fetal antigen-specific maternal T regulatory cell response that contributes to tolerance. Proc Natl Acad Sci U S A 2010;107(20):9299-304.

(22) Corthay A. How do regulatory T cells work? Scand J Immunol. 2009;70(4):326-36.

(23) Forger F, Marcoli N, Gadola S, Moller B, Villiger PM, Ostensen M. Pregnancy induces numerical and functional changes of CD4+CD25 high regulatory T cells in patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(7):984–90.

(24) Yael A, Dolhain RJ, Hazes JM. Disease activity or remission of rheumatoid arthritis before, during and following pregnancy. Current opinion in rheumatology. 2014;26(3):329-33.

(25) Van den Broek N, Letsky E. Pregnancy and the erythrocyte sedimentation rate. BJOG: An International Journal of Obstetrics & Gynaecology. 2001;108(11):1164-7.

(26) de Man YA, Hazes JM, van de Geijn FE, Krommenhoek C, Dolhain RJ. Measuring disease activity and functionality during pregnancy in patients with rheumatoid arthritis. Arthritis Care & Research: Official Journal of the American College of Rheumatology. 2007;57(5):716-22.

(27) Baffour FI, McKenzie GA, Bekele DI, Glazebrook KN. Sonography of active rheumatoid arthritis during pregnancy: a case report and literature review. Radiology Case Reports. 2018;13(6):1233-7.

(28) Ray JG, Vermeulen MJ, Bharatha A, Montanera WJ, Park AL. Association between MRI exposure during pregnancy and fetal and childhood outcomes. JAMA. 2016;316(9):952-61.

(29) Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural rogression. Arthritis Rheum. 2006;54(12):3761-73.

(30) Terslev L, Torp-Pedersen S, Savnik A, Recke Pvd, Qvistgaard E, Danneskiold-Samsoe B, et al. Doppler ultrasound and magnetic resonance imaging of synovial inflammation of the hand in rheumatoid arthritis: a comparative study. Arthritis Rheum. 2003;48(9):2434–41.

(31) D’Agostino MA, Terslev L, Aegerter P, Backhaus M, Balint P, Bruyn GA, et al. Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-Part 1: definition and development of a standardised, consensus-based scoring system. RMD Open. 2017;3(1):e000428.

(32) Wakefield RJ, Balint PV, Szkudlarek M, Filippucci E, Backhaus M, D’Agostino MA, et al. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol. 2005;32(12):2485-7.

(33) Skorpen CG, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Annals of the rheumatic diseases. 2016;75(5):795-810.

(34) Flint J, Panchal S, Hurrell A, Venne Mvd, Gayed M, Schreiber K, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice. Rheumatology. 2016;55(9):1698-702.

(35) Østensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis research & therapy. 2006;8(3):209.

(36) Panchal S, Khare M, Moorthy A, Samanta A. Catch me if you can: a national survey of rheumatologists and obstetricians on the use of DMARDs during pregnancy. Rheumatol Int. 2013;33(2):347-53.

(37) Rau R, Herborn G. A modified version of Larsen´s scoring method to assess radiologic changes in rheumatoid arthritis. J Rheumatol. 1995;22:1976-82.

(38) Backhaus M, Burmester G, Gerber T, Grassi W, Machold K, Swen W, et al. Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis. 2001;60:641–9.

(39) Duffy DM. Novel contraceptive targets to inhibit ovulation: the prostaglandin E2 pathway. Hum Reprod Update. 2015;21(5):652–70.

(40) Dathe K, Fietz AK, Pritchard LW, Padberg S, Hultzsch S, Meixner K, et al. No evidence of adverse pregnancy outcome after exposure to ibuprofen in the first trimester - evaluation of the national Embryotox cohort. Reprod Toxicol. 2018;79:32–8.

(41) Nakhai-Pour HR, Broy P, Sheehy O, Berard A. Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. CMAJ. 2011;183(15):1713–20.

(42) Viktil KK, Engeland A, Furu K. Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150, 000 pregnant women and expectant fathers. Scand J Rheumatol. 2012;41(3):196-201.

(43) Palmsten K, Hernandez-Diaz S, Kuriya B, Solomon DH, Setoguchi S. Use of disease-modifying antirheumatic drugs during pregnancy and risk of preeclampsia. Arthritis Care Res. 2012;64(11):1730-8.

(44) Bermas BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. Current opinion in rheumatology. 2014;26(3):334-40.

(45) Krause ML, Makol A. Management of rheumatoid arthritis during pregnancy: challenges and solutions. Open access rheumatology: research and reviews. 2016;8:23.

(46) Diav-Citrin O, Blyakhman S, Shechtman S, Ornoy A. Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study. Reproductive Toxicology. 2013;39:58-62.

(47) Sperber K, Hom C, Chao CP, Shapiro D, Ash J. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatric Rheumatology. 2009;7(1):9.

(48) Norgard B, Pedersen L, Christensen LA, Sorensen HT. Therapeutic drug use in women with Crohn’s disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol. 2007;102(7):1406-13.

(49) AAP. Pediatrics. Transfer of drugs and other chemicals into human milk. 2001;108(3):776–89.

(50) Kemp MW, Newnham JP, Challis JG, Jobe AH, Stock SJ. The clinical use of corticosteroids in pregnancy. Hum Reprod Update. 2016;22(2):240–59.

(51) Noviani M, Wasserman S, Clowse ME. Breastfeeding in mothers with systemic lupus erythematosus. Lupus. 2016;25(9):973-9.

(52) Weber-Schoendorfer C, Beck E, Tissen-Diabaté T, Schaefer C. Leflunomide–a human teratogen? A still not answered question. An evaluation of the German Embryotox pharmacovigilance database. Reproductive Toxicology. 2017;71:101-7.

(53) Chambers CD, Johnson DL, Robinson LK, Braddock SR, Xu R, Lopez‐Jimenez J, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis & Rheumatism. 2010;62(5):1494-503.

(54) Weber‐Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, Centers NoFP, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis & Rheumatology. 2014;66(5):1101-10.

(55) Weber Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, Centers NoFP, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis & Rheumatology. 2014;66(5):1101-10.

(56) Mozaffari S, Abdolghaffari A, Nikfar S, Abdollahi M. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis. Human & experimental toxicology. 2015;34(5):445-59.

(57) Rein P, Mueller RB. Treatment with biologicals in rheumatoid arthritis: an overview. Rheumatology and therapy. 2017;4(2):247-61.

(58) Siebert S, Tsoukas A, Robertson J, McInnes I. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacological reviews. 2015;67(2):280-309.

(59) Hodge J, Kawabata T, Krishnaswami S, Clark J, Telliez J, Dowty M, et al. The mechanism of action of tofacitinib-an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(2):318-28.

(60) Lai J-H, Ling XC, Ho L-J. Useful message in choosing optimal biological agents for patients with autoimmune arthritis. Biochemical pharmacology. 2019;165:99-111.

(61) Lau CS, Chia F, Dans L, Harrison A, Hsieh TY, Jain R, et al. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. International journal of rheumatic diseases. 2019;22(3):357-75.

(62) Tsao NW, Lynd LD, Sadatsafavi M, Hanley G, De Vera MA. Patterns of Biologics Utilization and Discontinuation Before and During Pregnancy in Women With Autoimmune Diseases: A Population Based Cohort Study. Arthritis care & research. 2018;70(7):979-86.

(63) Clowse ME. The use of anti-TNFα medications for rheumatologic disease in pregnancy. International journal of women‘s health. 2010;2:199.

(64) Luu M, Benzenine E, Doret M, Michiels C, Barkun A, Degand T, et al. Continuous anti-tnfα use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the French National Health Insurance Database (EVASION). The American journal of gastroenterology. 2018;113(11):1669.

(65) Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clinical and Developmental Immunology. 2011;2012.

(66) Lichtenstein GR, Feagan BG, Mahadevan U, Salzberg BA, Langholff W, Morgan GJ, et al. Pregnancy outcomes reported during the 13-Year TREAT registry: a descriptive report. The American journal of gastroenterology. 2018;113(11):1678.

(67) Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. Gastroenterology. 2018;155(3):696-704.

(68) Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499-506.

(69) Mandal PK, Dolai TK, Bagchi B, Ghosh MK, Bose S, Bhattacharyya M. B cell suppression in newborn following treatment of pregnant diffuse large B-cell lymphoma patient with rituximab containing regimen. The Indian Journal of Pediatrics. 2014;81(10):1092-4.

(70) Rubbert-Roth A, Goupille PM, Moosavi S, Hou A. First experiences with pregnancies in RA patients (pts) receiving tocilizumab (TCZ) therapy. Arthritis Rheum. 2010;62(Suppl 10):384.

(71) Gerosa M, Argolini LM, Artusi C, Chighizola CB. The use of biologics and small molecules in pregnant patients with rheumatic diseases. Expert review of clinical pharmacology. 2018;11(10):987-98.

(72) Clowse ME, Forger F, Hwang C, Thorp J, Dolhain RJ, Tubergen Av, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicenter, pharmacokinetic study. Ann Rheum Dis. 2017;76(11):1890–6.

(73) Andreoli L, Bertsias G, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women‘s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Annals of the rheumatic diseases. 2017;76(3):476-85.

(74) Shimada H, Kameda T, Kanenishi K, Miyatake N, Nakashima S, Wakiya R, et al. Effect of biologic disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis who hope to become mothers. Clinical rheumatology. 2019:1-6.

(75) Tsao NW, Sayre EC, Hanley G, Sadatsafavi M, Lynd LD, Marra CA, et al. Risk of preterm delivery and small-for-gestational-age births in women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study. Annals of the rheumatic diseases. 2018;77(6):869-74.

(76) van den Brandt S, Zbinden A, Baeten D, Villiger PM, Østensen M, Förger F. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients. Arthritis research & therapy. 2017;19(1):64.

Downloads

Download data is not yet available.